John S. Hostetler, MD
Subspecialty Education Director, Infectious Disease
Undergraduate: Pomona College, BA – Biochemistry
Medical: Medical College of Virginia, Richmond, Virginia
Residency: Kaiser Permanente Medical Center/Stanford University, Santa Clara, California – Internal Medicine
Fellowship: Stanford University, Stanford, California – Infectious Disease
Clinical Assistant Professor, Dept. of Family Practice, Mercer University School of Medicine
SOCIETIES & ORGANIZATIONS
Fellow, American College of Physicians
Fellow, Society of Hospital Epidemiologists
Member, Infectious Diseases Society of America
Member, Society of Hospital Epidemiologists of America
Member, International Travel Medicine Society
Hostetler JS, Hanson LH, and Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother. 1991 Feb;36:477-80.
Hostetler JS, and Stevens DA. [The treatment of aspergillosis, cryptococcosis and histoplasmosis in immunocompromised patients. Report of experience in the United States]. Med Klin 1991 Dec;86 Suppl 1:8-10.
Hostetler JS, Clemons KV, Hanson LH, and Stevens DA. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob Agents Chemother 1992 Dec;36:26656-60.
Hostetler JS, Denning DW, and Stevens DA. US experience with itraconazole in Aspergillus, Cryptococcus and Histoplasma infections in the immunocompromised host. Chemotherapy 1992;38 Suppl 1:12-22.
Kemper CA, Hostetler JS, Follansbee SE, Ruane P, Covington D, Leong SS, Deresinski SC, and Stevens DA. Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis. 1993 Sep;17:344-52.
Hostetler JS, Hanson LH, and Stevens DA. Effect of hydroxypropyl-beta-cyclodextrin on efficacy of oral itraconazole in disseminated murine cryptococcosis. J Antimicrob Chemother. 1993 Sep; 32:459-63.
Sharkey-Mathis PK, Kauffman CA, Graybill JR, Stevens DA, Hostetler JH, and others of the NIAID Mycoses Study Group. Treatment of sporotrichosis with itraconazole. Am J Med. 1993 Sept;95:279-85.
Hostetler JS, Heykants J, Clemons KV, Woestenborghs R, Hanson LH and Stevens DA. Discrepencies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agents Chemother. 1993 Oct;37:2224-7.
Hostetler JS, Brummer E, Coffman RL, and Stevens DA. Effect of anti-IL-4, interferon-gamma and an antifungal triazole (SCH 42427) in paracoccidioidomycosis: correlation of IgE levels with outcome. Clin Exp Immunol. 1993 Oct;94:11-6.
Hostetler JS, Catanzaro A, Stevens DA, Graybill JR, Sharkey PK, Larsen RA, Tucker RM, Al-Haidary AD, Rinaldi MG, Cloud GA, and Galgiani JN, NIAID Mycosis Study Group. Treatment of coccidioidomycosis with SCH 39304. J Med Vet Mycology 1994; 32:105-114.
Denning DW, Lee JY, Hostetler JH, Pappas PG, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Cantanzaro A, Gallis H, Perfect JR, Dockery B, Dismukes WE, Stevens DA and others of the NIAID Mycoses Study Group. Multicenter trial of oral itraconazole therapy of invasive aspergillosis. Am J Med 1994
Denning DW, Tucker RM, Hostetler JS, Gill SP, and Stevens DA. Oral itraconazole therapy of cryptococcal meningitis and cryptococcosis in patients with AIDS. 1991 p. 305-324. In H. Vanden Bossche et al. (ed.), Mycosis in AIDS Patients. Plenum Press, New York.